
TOKYO CHALLENGE 100 with Nippon Shinyaku Co.,Ltd.
About Nippon Shinyaku Co.,Ltd.
Based on the business philosophy “Helping people lead healthier, happier lives,” in our pharmaceutical segment, by focusing on our areas of specialty, we aim to become a company which provides quality and unique pharmaceuticals to help patients suffering from illnesses. Our areas of specialty for both R&D and marketing include urology, hematology, gynecology, otolaryngology and orthopedics. By implementing our own drug discovery research, licensing-in from other companies and product lifecycle management (PLCM), we are striving to speedily launch pharmaceuticals to help patients. Our drug discovery research is focused on the strategic fields such as urology and hematology, and on the elucidation of cause of new diseases.
Nippon Shinyaku Co.,Ltd. Challenges



Corporate Profile of Nippon Shinyaku Co.,Ltd.
Company Name | Nippon Shinyaku Co.,Ltd. |
Business Overview | Pharmaceuticals for medical homes, in-house drug discovery is concentrated in urology, hematology, intractable diseases and rare diseases. Cultivation of functional foods |
Type of Industry | Pharmaceutical |
URL | https://www.nippon-shinyaku.co.jp/english/ |
Collaboration results |
Jul.
2020
Fund investment results
1 billion yen invested in Biotech Fund newly established by Medical Incubator Japan Co., Ltd., an independent venture capital firm specializing in healthcare (headquarters: Minato-ku, Tokyo, President: Tsuji, "MIJ") Mar. 2019 Collaboration results Zogenix, Inc. (Headquarters: California, U.S.A., President and Chief Executive Officer: Stephen Farr) and ZX008, which is expected to be adaptive for Drabe syndrome and Lennox-Gasto syndrome, have an exclusive sales agreement in Japan. Mar. 2017 Collaboration results Delta-Fly Pharma Co., Ltd. (Headquarters: Tokushima City, President: Kiyoshi Ejima) acquires exclusive development and exclusive sales rights in Japan for DFP-10917, a recurrent and infunable acute myeloid leukemia (AML) treatment. |